Searchable abstracts of presentations at key conferences in endocrinology

ea0049ep620 | Diabetes therapy | ECE2017

Palpable purpura in an uncontrolled diabetic patient: an uncommon possible side effect of linagliptin

Topaloglu Omercan , Evren Bahri , Kara Mahmut , Yucel Seyfullah , Sahin Ibrahim

Introduction: Incretin based therapeutics have commonly been used in the last years for the management of patients with type 2 diabetes mellitus (DM). Linagliptin is a member of “dipeptidyl peptidase 4” (DPP-4) inhibitors and often preferred owing to some advantages over the others. We present a diabetic case developing skin findings after the initiation of linagliptin.Case: 66 year-old woman with a history of type 2 DM for 10 years was admitte...

ea0056p483 | Diabetes therapy | ECE2018

Maculopapular rash developed after initiation of U-300 glargine insulin in a patient with type 1 diabetes mellitus

Topaloglu Omecan , Evren Bahri , Bilgic Mehmet Akif , Kara Mahmut , Sahin Ibrahim

Introduction: U-300 insulin glargine has been used as a concentrated form of glargine. Skin and subcutaneous tissue disorders (eg, rash, pruritus, and urticaria) have been reported with insulin glargine. But to our knowledge, maculopapular rash has not been reported with use of U-300 insulin glargine. We present a patient with type 1 diabetes mellitus(DM) developing maculopapular rash after initiation of U-300 glargine insulin.Case Report: 37 year-old fe...